Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ddg.15444 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perineural botulinum toxin in the management of post-traumatic headache: a case report.
Rev Esp Anestesiol Reanim (Engl Ed)
September 2025
Physical Medicine and Rehabilitation. Universidad del Valle, Cali, Colombia; Interventional Pain Management, Fundalivio, Cali, Colombia.
Post traumatic headache is a common condition that can be managed with pharmacologic interventions or analgesic procedures; however, most evidence is derived from patients with mild trauma, leaving a large gap with regard to patients with moderate or severe trauma who present complex pain. Botulinum toxin plays an increasingly important role in pain management. This neurotoxin acts on different receptors, ranging from TRPV1 (transient receptor potential vanilloid type 1) to CGRP (calcitonin gene-related peptide).
View Article and Find Full Text PDFIs the Botulinum Toxin Injection Into the Cricopharyngeal Sphincter Precipitate Laryngopharyngeal Reflux Symptoms in Patients With Retrograde Cricopharyngeal Dysfunction?
J Voice
September 2025
Department of Otolaryngology - Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.
Objective: To investigate the potential relationship between retrograde cricopharyngeal dysfunction (R-CPD) and laryngopharyngeal reflux disease (LPRD) at baseline and whether cricopharyngeal sphincter paralysis botulinum toxin injection (BTI) is associated with an increase of LPRD symptoms in treated R-CPD patients.
Methods: Patients with clinical diagnosis of R-CPD were prospectively recruited from two European hospitals. Controls included individuals unable to burp without troublesome symptoms (CT1) and healthy subjects able to burp (CT2).
A Pilot Study of Differences in Antibody Responses of Intradermal and Intramuscular Injections of Botulinum Toxin Type A.
Dermatol Ther (Heidelb)
September 2025
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Introduction: Botulinum toxin type A (BoNT/A) is commonly used for both medical and aesthetic purposes. However, approximately 3% of long-term recipients develop resistance, potentially due to antibody formation. Injection technique may influence immunogenicity, yet comparative data remain limited.
View Article and Find Full Text PDFBotulinum toxins (BoNTs) are the most potent known bacterial toxins. The BoNT complex from Clostridium botulinum B-Okra (large progenitor toxin complex (L-PTC)/BOkra, hyper-oral-toxic) exerts at least 80-fold higher oral toxicity1 in mice compared with that from serotype A1 (L-PTC/A62A, non-hyper-oral-toxic). Here, we showed that L-PTC/BOkra was predominantly absorbed through enterocytes, whereas L-PTC/A62A targeted intestinal microfold cells.
View Article and Find Full Text PDFNeurogenic Voiding Dysfunction in Spinal Cord Injury and Stroke: Urodynamic Evaluation, Functional Classification, and Therapeutic Strategies.
Cureus
August 2025
General Medicine, Universidad de Ciencias Médicas (UCIMED), San José, CRI.
Many patients with injuries to their central nervous system, especially those who have had a stroke or a spinal cord injury, have neurogenic voiding dysfunction. It happens when patients can't control their bladder voluntarily, which can make them feel urgency, experience leaks, or have trouble emptying their bladder. If not treated right away, it can cause infections, damage to the bladder, or even kidney problems over time.
View Article and Find Full Text PDF